GOBARDEN Drug Patent Profile
Which patents cover Gobarden, and what generic alternatives are available?
Gobarden is a drug marketed by Avyxa Holdings and is included in one NDA.
The generic ingredient in GOBARDEN is bendamustine hydrochloride. There is one drug master file entry for this compound. Twelve suppliers are listed for this compound. Additional details are available on the bendamustine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Gobarden
A generic version of GOBARDEN was approved as bendamustine hydrochloride by ACCORD HLTHCARE on December 7th, 2022.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for GOBARDEN?
- What are the global sales for GOBARDEN?
- What is Average Wholesale Price for GOBARDEN?
Summary for GOBARDEN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| DailyMed Link: | GOBARDEN at DailyMed |
Pharmacology for GOBARDEN
| Drug Class | Alkylating Drug |
| Mechanism of Action | Alkylating Activity |
US Patents and Regulatory Information for GOBARDEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avyxa Holdings | GOBARDEN | bendamustine hydrochloride | SOLUTION;INTRAVENOUS | 219014-001 | Jul 3, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
